survivin peptide vaccine
Vaccineexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2003 (NCT00108875)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- survivin peptide vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02851056 | Early Phase 1 (Phase 1) | Aug 26, 2016 | University of South Florida |
| NCT00499577 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2006 | National Cancer Institute (NCI), University of Maryland |
| NCT00108875 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2003 | Julius-Maximilians University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Julius-Maximilians University | Academic/Hospital | 1 | 1 | 1 | 2003 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2006 |
| University of Maryland | Academic/Hospital | 1 | 1 | 1 | 2006 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2016 |
4 organizations
Page 1 / 1